7 min listen
Should Patients at High Risk of Peritoneal Dissemination from Gastric and Colon cancers Undergo HIPEC as an Adjuvant Therapy?
FromSurgOnc Today®
Should Patients at High Risk of Peritoneal Dissemination from Gastric and Colon cancers Undergo HIPEC as an Adjuvant Therapy?
FromSurgOnc Today®
ratings:
Length:
20 minutes
Released:
Apr 20, 2021
Format:
Podcast episode
Description
In this episode, Edward Levine, MD Chair of the SSO Peritoneal Surface Malignancy DSWG, is joined by Brian Badgwell, MD of MD Anderson Cancer Center and Pieter Tanis, MD, PhD of the University of Amsterdam. They discuss whether patients at high risk of peritoneal dissemination from gastric and colon cancers should undergo HIPEC as an adjuvant therapy.
Released:
Apr 20, 2021
Format:
Podcast episode
Titles in the series (99)
SSO Clinical Investigator Award: Perspectives from Tari King, MD: In this episode, Sandra Wong, MD, speaks with Tari King, MD, about the opportunities that stemmed from receiving the 2009 SSO Clinical Investigator Award. Dr. King shares her perspective on how to advance research and leadership career goals. by SurgOnc Today®